Showing results (91-100 of 176) with videos related to

Sort By:
Pageof 18
The Oncologist|June 8, 2012
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomasZhi-Yong Chen, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Therapeutic Advances in Medical Oncology|April 28, 2023
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patientsZhen Wang, Xu-Chao Zhang, Wei-Neng Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker AnalysesTony S K Mok, Sang-We Kim, Yi-Long Wu, et al.
JTO Clinical and Research Reports|September 16, 2024
Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA StudyCaicun Zhou, You Lu, Sang-We Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancerSi-Yang Liu, Zhong-Yi Dong, Si-Pei Wu, et al.
Frontiers in Oncology|December 28, 2020
Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung CancerJin Kang, Xu-Chao Zhang, Hua-Jun Chen, et al.
Nature Communications|January 13, 2026
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)Anna Li, Wei-Neng Feng, Juan Li, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastasesKai Yin, Yang-Si Li, Mei-Mei Zheng, et al.
Clinical Lung Cancer|May 5, 2010
Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma componentWen-Zhao Zhong, Yi-Long Wu, Xue-Ning Yang, et al.
Oncotarget|June 5, 2016
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancerLan-Ying Gou, An-Na Li, Jin-Ji Yang, et al.
Pageof 18